Henry H. Zhao

发表

Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1-Infected Patients (CAL30001 Study)

A. LaMarca, N. Clumeck, C. Craig, 2006, Journal of acquired immune deficiency syndromes.

Impact of Switch to Fosamprenavir and Addition of Lovaza ® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

B. Ha, H. Khanlou, L. Ross, 2012 .

Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

K. Squires, E. Dejesus, B. Young, 2010, HIV clinical trials.

Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study

P. Cahn, Steve A Castillo, G. Moyle, 2005, Journal of acquired immune deficiency syndromes.

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With In ﬂ uenza: An Open-label, Multicenter, Single-Arm, Phase II Study

D. Brealey, J. Lorente, P. Yates, 2014 .

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

K. Squires, E. Dejesus, N. Bellos, 2010, AIDS.

Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.

P. Yates, Nalini A. L. Mehta, Henry H. Zhao, 2016, Antiviral research.

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine

A. LaMarca, K. Tashima, K. Squires, 2015, HIV clinical trials.

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study

D. Brealey, J. Lorente, P. Yates, 2013, The Journal of infectious diseases.

Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy

J. Atashili, V. Vannappagari, Henry H. Zhao, 2011 .

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

D. Ward, K. Squires, E. Dejesus, 2012, HIV clinical trials.

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

K. Squires, D. Margolis, G. E. Pakes, 2012, AIDS research and human retroviruses.

Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy.

J. Atashili, V. Vannappagari, Henry H. Zhao, 2011, Platelets.

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

D. Wohl, E. Dejesus, D. Margolis, 2014, PloS one.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

K. Squires, S. Walmsley, G. E. Pakes, 2017, HIV/AIDS.

The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis Among Indian Children

P. Karakousis, V. Mave, Amita Gupta, 2022, Frontiers in Immunology.

Hiv/aids -research and Palliative Care Dovepress Response by Gender of Hiv-1-infected Subjects Treated with Abacavir/lamivudine plus Atazanavir, with or without Ritonavir, for 144 Weeks on Behalf of the Aries Study Team

K. Squires, S. Walmsley, G. E. Pakes, 2022 .

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir†

D. Wohl, E. Dejesus, L. Bhatti, 2015, HIV medicine.